Genentech/MedImmune Patent Case Could Spur Tighter Licensing Deals

Supreme Court ruling that MedImmune can challenge the validity of a patent it had licensed could also encourage generic firms to seek declaratory judgments.

More from Archive

More from Pink Sheet